Open house Rituximab discount agreements

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Oct 05, 2026 · 36 days left·Open·Supplies·Framework

Inscrivez-vous pour sauvegarder Open documents

Structured notice only

Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rituximab, ATC L01FA01

40/100

Score d'opportunité

Needs reviewLow complexity

SuppliesFrameworkOpen

Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or volume commitment; participation does not guarantee any sales or revenue.

Agreements may be superseded by a nationwide or region-wide competitive discount contract for the same active substance...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Aperçu

Moderate opportunity

Faits clés

Framework procurement
Supplies contract
1 lot
Duration until Nov 2026
Supply of pharmaceutical products containing Rituximab (ATC L01FA01) to AOK Bayern
Non-exclusive discount agreements under §130a Abs. 8 SGB V

Afficher le résumé complet

Open-house model for non-exclusive discount agreements for the active substance Rituximab (ATC L01FA01) with AOK Bayern. This is not a public procurement procedure but a voluntary agreement under §130a Abs. 8 SGB V. All interested pharmaceutical companies meeting eligibility can join. No estimated value or award criteria provided as all eligible participants are accepted. Contract duration from 01.12.2024 to 30.11.2026, with possible earlier termination if a competing nationwide discount agreement takes effect.

Risques

No estimated value or volume commitment; participation does not guarantee any sales or revenue.

Agreements may be superseded by a nationwide or region-wide competitive discount contract for the same active substance...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

Must be a pharmaceutical company (pharmazeutischer Unternehmer)
Provide signed contract and annex defining covered medicines

Administrative

Submit signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)

Les exigences peuvent être incomplètes.

Acheteur

Nom

AOK Bayern - Die Gesundheitskasse

Localisation

München, DEU

[email protected]

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Rituximab discount agreements

Open-house model for non-exclusive discount agreements for Rituximab. The AOK Bayern offers identical, non-negotiable contracts to all interested pharmaceutical companies that meet the eligibility criteria.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Nov 2024 - Nov 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Oct 05, 2026

Détails de la procédure

Date de publication: 16 Oct 2024
Langues: German

Métadonnées de référence

Base juridique: 32014L0024

Identifiants de référence

ID de l'appel d'offres: 627573-2024

Documents (2)

Document de consultation 1 Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3